-
FDA grants fast-track designation to new flu prevention drug
The FDA has given a fast-track designation to a drug designed to prevent infection from both influenza A and B strains created by San Diego-based Cidara Therapeutics, according to a June 22 news release. -
FDA approves 1st gene therapy for Duchenne muscular dystrophy
The FDA approved the first gene therapy for some pediatric patients with Duchenne muscular dystrophy, a rare genetic condition that weakens the body's muscles, on June 22. -
CDC panel greenlights RSV shot for older adults
People 60 and older "may" get a respiratory syncytial virus vaccine — that is what a CDC advisory panel voted June 21, stopping short of what was anticipated to be a stronger recommendation that older adults "should" get the shots. -
New Hampshire hospital fined $2M in missing fentanyl case
Keene, N.H.-based Cheshire Medical Center will pay $2 million in connection with an incident in which gallons of fentanyl solution were lost or unaccounted for in a four-month period. -
Half of active pharmaceutical ingredients made overseas: 10 notes
Fifty-two percent of active pharmaceutical ingredients used in U.S. medications are made outside the country, according to an annual report from the FDA. -
FDA approves 2 drugs for pediatric Type 2 diabetes treatment
The FDA granted full approval to two drugs June 20 — Jardiance and Synjardy, both manufactured by Boehringer Ingelheim — for the treatment of pediatric Type 2 diabetes. Now, children with the condition will have three options for approved therapies. -
UPMC to help build new drug R&D facility
UPMC is teaming up with PharmaLogic Holdings to construct one of the largest U.S.-based facilities for radiopharmaceutical research, production and distribution in Pittsburgh, the two organizations said June 21. -
Cone Health has a new chief pharmacy officer
Cone Health tapped Andre Harvin, PharmD, as its new chief pharmacy officer June 21. -
Eli Lilly to acquire Dice Therapeutics for $2.4B
Eli Lilly plans to acquire Dice Therapeutics — a biopharmaceutical company that develops oral therapeutics for autoimmune diseases — in a deal valued at $2.4 billion. -
Louisiana enacts law to protect 340B contract pharmacies
Louisiana passed a bill that prevents drugmakers from restricting 340B-discounted drugs to safety-net hospitals' contract pharmacies. The law is effective Aug. 1. -
Nurses can now certify their jump to pharmacy work
The Accreditation Council for Medical Affairs on June 20 unveiled the first and only accredited certification for nurses wanting to transition to the biopharmaceutical industry. -
Why drug shortages might worsen
FDA investigators discovered more quality issues at an Intas Pharmaceuticals factory in Ahmedabad, India, which halted some production after a November inspection found a truck full of shredded documents, Bloomberg reported June 15. -
5 deaths partially halt drug trial
In two days, two Cambridge, Mass.-based pharma companies have paused their cancer drug trials after six patients died. -
Michigan drugmaker recalls meds in wrong package
Major Pharmaceutical/Rugby Laboratories, based in Livonia, Mich., is recalling one lot of an anti-nausea drug because a distributor found it to be mislabeled as the drugmaker's schizophrenia drug. -
40% of ulcerative colitis patients in clinical trial reached remission with AbbVie drug
A 52-week phase 3 clinical trial of Skyrizi, or risankizumab — a drug initially approved to treat Crohn's disease, psoriatic arthritis and psoriasis — was shown to also achieve clinical remission in 40 percent of patients with ulcerative colitis, AbbVie announced June 15. -
Preparing for new USP standards: 5 things to know
On Nov. 1, the new U.S. Pharmacopoeia standards on sterile and nonsterile compounding will be implemented. Here's what leaders need to know about USP 795 and USP 797: -
Inflation Reduction Act projected to save cancer patients $7,590 every year
The Inflation Reduction Act could offer cancer patients annual savings of $7,590 on average, and some patients could save up to $19,296, according to a June 14 report from Patients for Affordable Drugs. -
Seattle Children's, drug company pause trial after patient death
Seattle Children's Hospital paused a sponsored clinical study of a leukemia drug candidate after the first patient to take the medication died, according to the oncology cell-therapy company 2seventy Bio. -
Cost Plus Drugs ends plan to sell insulin
Mark Cuban Cost Plus Drug Co. considered selling insulin but found the price doubled with shipping costs, CEO and co-founder Alex Oshmyansky, MD, PhD, said June 13 at the AHIP conference. -
Connecticut pharmacists can now prescribe birth control
Connecticut Gov. Ned Lamont signed a bill June 13 allowing pharmacists to prescribe birth control without a patient being required to visit a physician.
Page 42 of 50